Alternatives to lisdexamfetamine
FDA shortage status is active for lisdexamfetamine; 3 same-class SPL records are listed below for registry comparison only.
Brand: Vyvanse
lisdexamfetamine class peers while FDA lists an active shortage
lisdexamfetamine (Vyvanse) is on an FDA shortage listing while 3 other CNS Stimulant SPL records remain in this registry peer set (class inventory 4). Labeled indication field for lisdexamfetamine: This medicine treats Attention Deficit Hyperactivity Disorder (ADHD) in adults and kids 6 years and older.
Top FAERS reaction fields for lisdexamfetamine total 4,963 reports across 10 reactions, set beside amphetamine/dextroamphetamine, dexmethylphenidate, methylphenidate. Counts are exposure-weighted submissions, not per-patient risk.
About lisdexamfetamine
Lisdexamfetamine (Vyvanse) is a stimulant medicine. It can help improve focus and reduce impulsive behavior.
Used for: This medicine treats Attention Deficit Hyperactivity Disorder (ADHD) in adults and kids 6 years and older. It also treats moderate to severe binge eating disorder (BED) in adults. This medicine is not for weight loss.
3 CNS Stimulant peers (wide set)
amphetamine/dextroamphetamine
RxAdderall, Adderall XR
Adderall XR treats attention deficit hyperactivity disorder (ADHD) in adults and kids 6 years and older. ADHD can make it hard to focus, pay attention, and control impulsive behavior. This medicine can help improve focus and reduce impulsivity.
dexmethylphenidate
RxFocalin, Focalin XR
AZSTARYS is used to treat Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years and older. ADHD can make it hard to focus, pay attention, and control impulsive behaviors. This medicine can help manage these symptoms.
methylphenidate
RxRitalin, Concerta
This medicine treats Attention Deficit Hyperactivity Disorder (ADHD) in children. ADHD can make it hard to focus, pay attention, and control impulsive behavior. This medicine can help improve focus and reduce hyperactivity.
Compare lisdexamfetamine vs amphetamine/dextroamphetamine side-by-side →
lisdexamfetamine vs amphetamine/dextroamphetamine & dexmethylphenidate · FAERS reaction fields
FAERS top-reaction field "Intentional Overdose" shows the widest count spread between lisdexamfetamine and amphetamine/dextroamphetamine, dexmethylphenidate, methylphenidate in this extract (1,068-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | lisdexamfetamine | amphetamine/dextroamphetamine | dexmethylphenidate | methylphenidate |
|---|---|---|---|---|
| Intentional Overdose | 1,068 | - | - | - |
| Intentional Self-Injury | 1,009 | - | - | - |
| Product Availability Issue | 487 | - | - | - |
| Fatigue | 402 | - | 169 | 823 |
| Headache | 377 | 190 | 183 | 808 |
| Anxiety | 357 | - | 189 | 833 |
| Inability To Afford Medication | 348 | - | - | - |
| Product Substitution Issue | 344 | - | 102 | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
lisdexamfetamine shortage vs CNS Stimulant peer index
Shortage status
FDA shortage listing is active for lisdexamfetamine (status: Current). Peer rows remain a registry index, not a switch guide.
Frequently Asked Questions
Does FDA list a shortage for lisdexamfetamine while peers remain indexed? ▼
Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for lisdexamfetamine: see also the generic vs brand label guide when reading Vyvanse SPL strings.
Read our methodology - how this data is sourced, computed, and verified.